Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Home
About
Overview
Open Source Software
Help
History (1)
Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism.
See All Pages
Find People
Find Everything
Login
to
edit your profile
(add a photo, education, awards, etc.), search
student opportunities
, and
create reports
.
Edit My Profile
My Person List (
0
)
Opportunity Search
Return to Top
Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism.
Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism. Crit Pathw Cardiol. 2011 Jun; 10(2):84-6.
View in:
PubMed
subject areas
Administration, Oral
Anticoagulants
Atrial Fibrillation
Benzimidazoles
beta-Alanine
Biopharmaceutics
Blood Coagulation
Clinical Trials, Phase III as Topic
Drug Approval
Drug Dosage Calculations
Drug Monitoring
Humans
Risk Assessment
Therapeutic Equivalency
Thrombin
Thromboembolism
Warfarin
authors with profiles
Christopher Paul Cannon, M.D.